Omacetaxine in Gleevec-resistant CML therapy continues to impress
According to the results of a small study presented at the American Society of Hematology meeting this weekend, omacetaxine, the investigational drug under development by ChemGenex Pharmaceuticals Limited to treat patients with T315I-positive chronic myeloid leukemia, continues to improve upon its safety profile and efficacy.
Although Gleevec is first-line therapy for chronic myeloid leukemia, some patients have a genetic mutation (T315I) that makes them Gleevec-resistant. Researchers at ChemGenex believe that omacetaxine holds great promise for these patients.
Although currently only used to treat leukemia in China and not approved in Europe or the US, the FDA recently fast-tracked omacetaxine.
Presented as an abstract, until published in a peer-reviewed journal the conclusions of this study are considered preliminary only.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
